Gastric cancer is the third leading cause of cancer mortality worldwide. As surgery is the only curative treatment strategy and conventional chemotherapy has shown limited efficacy -with a median overall survival of 10 months- new treatments are urgently needed. Trastuzumab and Ramucirumab (targeting HER2 and VEGFR2, respectively) are the only targeted therapies approved so far. Indeed, most Phase III clinical trials evaluating molecular drugs in gastric cancer failed. This review will retrace the relevant clinical trials with molecular therapies performed in gastric cancer patients, discussing the possible reasons for their failure and indicating new perspective for a real improvement of the treatment of this disease.

Targeted therapies for gastric cancer: failures and hopes from clinical trials

APICELLA, MARIA;CORSO, Simona
Co-first
;
GIORDANO, Silvia
Last
2017

Abstract

Gastric cancer is the third leading cause of cancer mortality worldwide. As surgery is the only curative treatment strategy and conventional chemotherapy has shown limited efficacy -with a median overall survival of 10 months- new treatments are urgently needed. Trastuzumab and Ramucirumab (targeting HER2 and VEGFR2, respectively) are the only targeted therapies approved so far. Indeed, most Phase III clinical trials evaluating molecular drugs in gastric cancer failed. This review will retrace the relevant clinical trials with molecular therapies performed in gastric cancer patients, discussing the possible reasons for their failure and indicating new perspective for a real improvement of the treatment of this disease.
1
10
http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=14825&pubmed-linkout=1
HER2; gastric cancer clinical trials; immunotherapy; targeted therapies; tyrosine kinase receptors
Apicella, Maria; Corso, Simona; Giordano, Silvia
File in questo prodotto:
File Dimensione Formato  
Apicella Corso Giordano Oncotarget 2017 - 28148892.pdf

Accesso aperto

Descrizione: ONCOTARGET 2017 APERTO
Tipo di file: PDF EDITORIALE
Dimensione 2.63 MB
Formato Adobe PDF
2.63 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1634116
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 89
  • ???jsp.display-item.citation.isi??? 82
social impact